Zeprumetostat clinical trials
Zeprumetostat is named as an intervention in 20 current clinical trials in our China, USA, Canada and Australia registers. 13 are recruiting patients now. The most common phase is Phase 2. The sponsor with the most trials is Jiangsu HengRui Medicine Co., Ltd (6). The most-studied condition is Lymphoma.
How Zeprumetostat works
All drug targets →- Mature T-cell and NK-cell non-Hodgkin lymphomaPhase 3
- Acute lymphoblastic leukemiaPhase 2
- Acute myeloid leukemiaPhase 2
- Breast cancerPhase 2
- Colorectal cancerPhase 2
- Follicular lymphomaPhase 2
- Gastric adenocarcinomaPhase 2
- Gastric cancerPhase 2
- Gastroesophageal junction adenocarcinomaPhase 2
- Myelodysplastic syndromePhase 2
Mechanisms and diseases from ChEMBL via the Open Targets Platform (release 26.09), ChEMBL record CHEMBL5939817, CC BY-SA 3.0. Targets checked against the IUPHAR/BPS Guide to PHARMACOLOGY (2026.3.1), ligand 13512, CC BY-SA 4.0. Trial phases are not approvals: approved uses are shown from the regulators' own records where we hold them.
Patient leaflets for Zeprumetostat
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Trials by status
Trials by phase
Clinical trials of Zeprumetostat
20 trialsRegisters list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Conditions studied with Zeprumetostat
24 conditionsAll 24 conditions
| Condition (as registered) | Trials |
|---|---|
| Lymphoma | 2 |
| Follicular Lymphoma | 2 |
| Advanced Gastric Cancer | 2 |
| Prostate Cancer | 2 |
| Lymphoma, Non Hodgkin | 1 |
| Peripheral T-cell Lymphoma (PTCL) | 1 |
| Bladder Urothelial Carcinoma | 1 |
| Bladder Cancer | 1 |
| PTCL-NOS | 1 |
| Large Granular Lymphocyte Leukemia | 1 |
| T-LGL Leukemia | 1 |
| Extranodal NK/T-cell Lymphoma | 1 |
| NK/T-cell Lymphoma | 1 |
| Relapsed or Refractory NK/T-Cell Lymphoma | 1 |
| Peripheral T Cells Lymphoma (PTCL) | 1 |
| Cutaneous T-Cell Lymphoma/Mycosis Fungoides/Sézary Syndrome | 1 |
| SHR1701 | 1 |
| PTCL | 1 |
| Advanced Breast Cancer | 1 |
| Metastatic Gastric Cancer | 1 |
| Gastroesophageal Junction Adenocarcinoma | 1 |
| Colorectal Cancer Metastatic | 1 |
| Locally Advanced or Metastatic Non-small Cell Lung Cancer | 1 |
| Relapsed/Refractory PTCLT With at Least One Line of Prior Systemic Therapy | 1 |
Sponsors
lead sponsor per trialBy country register
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 18 | 12 |
| Clinical trials in USA | 2 | 1 |
| Clinical trials in Canada | 2 | 1 |
| Clinical trials in Australia | 1 | 1 |
A trial with sites in more than one country appears in each of those registers.
Related compounds
Questions about Zeprumetostat trials
How many clinical trials are testing Zeprumetostat?
20 current trials in our China, USA, Canada and Australia registers name Zeprumetostat (also registered as TLN-254) as a drug or biological intervention, as of the registry sync on 10 November 2026. Completed and withdrawn studies are not counted.
Are Zeprumetostat trials recruiting patients?
Yes. 13 of the 20 trials are recruiting: 12 with sites in China, 1 with sites in USA, 1 with sites in Canada and 1 with sites in Australia. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Who sponsors Zeprumetostat clinical trials?
Jiangsu HengRui Medicine Co., Ltd (6), Treeline Biosciences, Inc (2), Institute of Hematology & Blood Diseases Hospital, China (2) and Ruijin Hospital (1), among 13 lead sponsors in total. The number in brackets is how many trials each organisation leads.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Zeprumetostat works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Zeprumetostat works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Zeprumetostat (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 10 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.